Favorable Immune Reconstitution in Patients Administered Anti-Thymocyte Globulin (ATG) Early in the Course of Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation

胸腺球蛋白 抗胸腺细胞球蛋白 医学 移植 内科学 移植物抗宿主病 胃肠病学 队列 氟达拉滨 全身照射 免疫学 梅尔法兰 造血干细胞移植 阿勒姆图祖马 化疗 环磷酰胺 他克莫司
作者
Viktoriya Zelikson,Natasha Raman,Anatevka Rebiero,Elizabeth Krieger,Catherine Roberts,Gary Simmons,Amir A. Toor
出处
期刊:Blood [Elsevier BV]
卷期号:136 (Supplement 1): 16-17
标识
DOI:10.1182/blood-2020-138581
摘要

Anti-thymocyte globulin (ATG) mitigates graft vs host disease (GVHD) risk in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Due to T cell depletion there remains a concern that ATG administration may be associated with an increased risk of malignancy, relapse, and infection in recipients of reduced intensity conditioning (RIC). It was hypothesized that ATG infusion early in the course of conditioning will promote rapid immune reconstitution because of lower levels at the time of graft infusion and will thus help to improve clinical outcomes in RIC. Rabbit ATG (Thymoglobulin, Sanofi Aventis) was administered from day (d) -9 to -7 to HLA matched-unrelated (MUD; 5 mg/kg in divided doses) and -related (MRD; 3.5 mg/kg) donor transplant recipients conditioned with Fludarabine and Melphalan (ATG -9 cohort; N=36). Immune reconstitution and clinical outcomes were compared with a historical control group of patients who received the same doses of ATG from d-3 to -1 (ATG -3 cohort; N=28). Standard GVHD prophylaxis with calcineurin inhibitor and antimetabolite was administered, with CMV and EBV monitoring. ATG -9 cohort had more, MUD recipients 80% vs. 64%; myeloid malignancy (AML, MDS, MPD) 83% vs. 35%. Age (56 vs. 57), graft type (97 vs. 92% PBSC) and CD34+cell dose infused (4.8 vs 4.7 E6/KG) were similar. Immune reconstitution was uniformly superior in ATG -9 cohort, with significantly higher absolute monocyte counts (AMC) at d30, 60 and 90 (P<0.001), as well as higher donor derived CD3+ (ddCD3+) and CD3+/8+ cell counts at d60 and 90 (P<0.01), and CD3+/4+ cells at d90 (P=<0.05). T cell - monocyte interactions were modelled as 2 dimensional vectors in the immune phase space, (Figure 1) with a consistently higher vector magnitude observed in ATG-9 cohort (P<0.01). Rate of T cell reconstitution was determined by calculating the derivative of ddCD3+ cell count as a function of time (dT/dt) post-transplant (Figure 2) and was generally higher in the ATG-9 cohort, particularly at d60. With a median follow up of 14.9 months in the ATG-9 cohort, and 47.2 months in the ATG -3 cohort, there is a non-significant trend for improved survival (72.2% vs. 46.4% at 2 years) and relapse (19.4% vs. 35.7% at 2 years) in the ATG -9 cohort. TRM and acute GVHD were similar, with a trend towards greater risk for chronic GVHD in the ATG -9 cohort, albeit of a lower severity. Given the relatively low number of patients in each cohort, the effect of immune reconstitution on clinical outcomes was evaluated in the pooled population. Survival was improved in those with AMC and ddCD3+ cell counts >200/µL at d60 (P=0.004 & 0.016 respectively), and in patients with T cell - monocyte vector magnitude > median (577.48/µL) at that time (P= 0.008), as well as in those with a calculated dT/dt > median (1.96 cells/µL/day) at d45 (P=0.047). The latter was also associated with a reduction in relapse rate (P=0.04), as was ddCD8+ cell count >145/µL at d60 (P=0.04). Acute GVHD risk was increased when dT/dt was >median (7.60 cells/µL/day) at d15 (P=0.0095), and correspondingly with T cell - monocyte vector magnitude > median (1033.3/µL) at d30 (P=0.017). In conclusion, this retrospective study demonstrates that equal doses of ATG administered earlier (d -9 to -7 as opposed to d-1 to -3) during conditioning yield more rapid and robust immune reconstitution. Monocyte and ddCD3+ cell recovery kinetics have a favorable impact on survival and relapse risk following HLA matched HCT. Patients at risk for acute GVHD may be identified as early as d15 post HCT by analyzing ddCD3+ cell reconstitution kinetics. Different ATG administration schedules should be studied prospectively with a focus on immune reconstitution kinetics as a determinant of clinical outcomes. Disclosures No relevant conflicts of interest to declare. OffLabel Disclosure: Rabbit anti-thymocyte globulin for GVHD prophylaxis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被111采纳,获得10
刚刚
弓长广发完成签到,获得积分10
刚刚
刚刚
2秒前
2秒前
2秒前
yummy发布了新的文献求助10
3秒前
苏凉发布了新的文献求助10
4秒前
焱焱不忘完成签到 ,获得积分0
4秒前
Jun的应助被无辜冷雁采纳,获得10
4秒前
4秒前
念青唐发布了新的文献求助10
4秒前
vv发布了新的文献求助10
5秒前
Brandy完成签到,获得积分10
5秒前
魁梧的熊猫完成签到,获得积分10
5秒前
米米发布了新的文献求助10
6秒前
cc晒泰阳发布了新的文献求助10
6秒前
归一完成签到 ,获得积分10
6秒前
猪猪hero发布了新的文献求助10
6秒前
Dongcong完成签到,获得积分0
6秒前
saveMA完成签到,获得积分10
7秒前
稳重的道天完成签到,获得积分10
8秒前
8秒前
9秒前
李健的小迷弟的应助被玩家666采纳,获得10
9秒前
xigu发布了新的文献求助10
9秒前
坚强从筠完成签到,获得积分20
9秒前
胜似闲庭信步完成签到,获得积分10
10秒前
10秒前
ZZZZ完成签到,获得积分10
10秒前
小二郎的应助被luhanwei采纳,获得10
10秒前
归一关注了科研通微信公众号
10秒前
纤维砖家发布了新的文献求助10
10秒前
孝顺的猫完成签到,获得积分10
10秒前
语兰完成签到 ,获得积分10
11秒前
11秒前
傻傻的初柳完成签到,获得积分10
11秒前
香蕉觅云的应助被孤独代亦采纳,获得10
12秒前
12秒前
luo发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695